<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-480
Date of Submission: 2025-03-13

This report was submitted by a Patient from Nixon-Reyes Medical Center concerning patient ANON-PX-4185. The subject is a 36-year-old female with a significant medical history including seasonal allergies, hypertension, atrial fibrillation, asthma. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Metformin (Biguanide) administered via the Intravenous route at a dosage of 470mg, initiated on 2025-01-05 for Type 2 diabetes and discontinued on 2025-02-25.

On approximately 2025-02-24, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Headache, Vomiting, Dizziness. The Headache was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Vomiting was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed performance and advised science. The current patient status regarding this symptom is 'Recovering'. The Dizziness was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review. 

</data>
report_id: ADR-2025-480
report_date: '2025-03-13'
patient_details:
  patient_id: ANON-PX-4185
  gender: Female
  relevant_history:
  - seasonal allergies
  - hypertension
  - atrial fibrillation
  - asthma
  age_at_reaction: 36
suspected_drugs:
- drug_name: Metformin
  dosage: 470mg
  route_of_administration: Intravenous
  start_date: '2025-01-05'
  indication_for_use: Type 2 diabetes
  drug_class: Biguanide
  end_date: '2025-02-25'
adverse_reactions:
- symptom_name: Headache
  onset_date: '2025-02-24'
  severity: Severe
  outcome: Fatal
  intervention_required: false
- symptom_name: Vomiting
  onset_date: '2025-02-24'
  severity: Life-threatening
  outcome: Recovering
  intervention_required: true
  intervention_details: Prescribed performance and advised science.
- symptom_name: Dizziness
  onset_date: '2025-02-24'
  severity: Moderate
  outcome: Unknown
  intervention_required: true
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Rechallenge not performed
reporting_facility: Nixon-Reyes Medical Center
reporter_type: Patient
